Patrick Van Beneden

Patrick has extensive experience in Life Sciences and AgTech through his long-term career with the leading European investment firm Gimv, where he has built a successful track record in early and late stage investments and exits, including DevGen, CropDesign, Plexxikon and Endosense. Gimv (listed on Euronext Brussels) was established almost four decades ago and invests in private companies that fit into one of their four investment platforms: Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. Patrick is currently representing Gimv on the Boards of JenaValve, Complix, Biotalys, G-Therapeutics and Fire1. Former Board seats include Innogenetics, Crucell, Hypnion (acquired by Eli Lilly), CropDesign (acquired by BASF), Astex and Ablynx (acquired by Sanofi). Patrick has a Degree in Financial Sciences from Vlekho in Brussels, Belgium.